One of the global leaders in pharmaceuticals, Israel-based Teva Pharmaceutical Industries Ltd., recently revealed their sponsorship of 14 abstracts of studies on their well-established multiple sclerosis treatments COPAXONE® and laquinimod.
The abstracts were presented at the 66th annual American Academy of Neurology (AAN) conference in Philadelphia, and, according to Teva, successfully added recently developed information on the clinical benefits of a thrice-a-week COPAXONE® 40mg/mL regimen for multiple sclerosis patients. The studies also shed light on its effectiveness, safety, and tolerability.
COPAXONE® is an injection of glatiramer acetate and is used to treat individuals with relapsing forms of multiple sclerosis. The findings from an open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) experiment, based on a comparison of the drug’s safety and tolerability under the recent trice-a-week COPAXONE® 40 mg/mL with a daily dose of 20mg/mL, were exhibited during an oral presentation by chief investor, Dr. Jerry Wolinsky, a Bartels Family and Opal C. Rankin Professor of Neurology at The University of Texas Medical School in Houston. Dr. Wolinsky has been involved in other multiple sclerosis research, including a newly-discovered link between HIV and MS that may suggest new treatment options.
Teva Pharmaceutical Industries, Ltd.’s president and chief scientific officer, Dr. Michael Hayden, said that, “the clinical and real-world significance of the data presented underscore Teva’s commitment to developing solutions to address unmet patient needs.” Furthermore, he added that, “our deep understanding of MS patients’ needs, keeps us at the leading edge of MS therapy development, with a single-minded focus on supporting the MS community in the provision of the highest standards of care possible, now and in the future.”